Martin Skreli is a name that has been in the news for all the wrong reasons. He is a controversial figure who has been involved in multiple controversies related to his business practices. Skreli is a former hedge fund manager and pharmaceutical executive who has been called the "most hated man in America."
The Purchase
Recently, it was revealed that Skreli had purchased the manufacturing licensure for a drug used to treat parasitic infections. The drug, called Daraprim, had been in the news in 2015 when Skreli's former company, Turing Pharmaceuticals, raised the price of the drug from $13.50 to $750 per pill.
The Outrage
The move was widely criticized and Skreli faced a lot of public outrage. He was even called to testify in front of the US Congress, where he was grilled over his business practices. Skreli was eventually convicted of securities fraud in 2017 and sentenced to seven years in prison.
The Sale
After his conviction, Skreli was forced to forfeit $7.4 million in assets, including the manufacturing licensure for Daraprim. The licensure was put up for sale and Skreli, who was still in prison at the time, managed to purchase it for $2 million.
The Response
The news of Skreli's purchase was met with mixed reactions. Some criticized the sale, arguing that Skreli should not be allowed to profit from his past actions. Others defended Skreli, saying that he had a right to purchase the licensure like anyone else.
The Future of Daraprim
Now that Skreli owns the manufacturing licensure for Daraprim, it remains to be seen what he will do with it. Some have speculated that he may try to raise the price of the drug again, while others believe that he may use it to negotiate with other pharmaceutical companies.
The Backlash
Regardless of what Skreli does with the licensure, it is clear that he will face a lot of backlash from the public. Many have already taken to social media to express their anger over the sale, with some calling for a boycott of any products associated with Skreli.
The Lessons Learned
The controversy surrounding Martin Skreli and the sale of the Daraprim licensure serves as a reminder of the importance of ethical business practices. Skreli's actions were widely criticized and resulted in legal consequences. It is important for businesses to prioritize ethical behavior and to consider the impact of their actions on the wider community.
The Conclusion
In conclusion, Martin Skreli's purchase of the manufacturing licensure for Daraprim has once again brought him into the spotlight. While some defend his right to purchase the licensure, others are outraged that he has been allowed to profit from his past actions. Only time will tell what Skreli will do with the licensure, but it is clear that he will continue to be a controversial figure in the world of business and pharmaceuticals.
Related video of Martin Skreli Bought The Manufacturing Licensure